Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C

Background/Aims: Treatment regimens with pegylated interferons have yielded improved response rates, compared with conventional interferon-based regimens, for chronic hepatitis C. However, little is known about the utility of such regimens for individuals who failed to respond to prior conventional...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2005-08, Vol.43 (2), p.243-249
Hauptverfasser: Krawitt, Edward L., Ashikaga, Takamaru, Gordon, Stuart R., Ferrentino, Nicholas, Ray, Mary Ann, Lidofsky, Steven D.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antiviral Agents - therapeutic use
Biological and medical sciences
Chronic hepatitis
Cirrhosis
Drug Resistance, Viral
Drug Therapy, Combination
Female
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Genotype
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis C
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Human viral diseases
Humans
Immunomodulators
Infectious diseases
Interferon
Interferon alpha-2
Interferon-alpha - therapeutic use
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Pharmacology. Drug treatments
Polyethylene Glycols
Polymerase Chain Reaction
Prospective Studies
Recombinant Proteins
Ribavirin
Ribavirin - therapeutic use
RNA, Viral - drug effects
Treatment Outcome
Viral diseases
Viral hepatitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background/Aims: Treatment regimens with pegylated interferons have yielded improved response rates, compared with conventional interferon-based regimens, for chronic hepatitis C. However, little is known about the utility of such regimens for individuals who failed to respond to prior conventional interferon-based treatment.Methods: 182 patients who had previously failed to eliminate circulating hepatitis C virus 24 weeks after completion of a multi-week course of either interferon monotherapy or interferon in combination with ribavirin were treated with peginterferon alfa-2b weekly and ribavirin daily for 48 weeks.Results: The sustained viral response, was 20% (23/116) in previous non-responders and 55% (36/66) in previous relapsers (P
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2005.03.015